News|Videos|November 20, 2023
Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab
Author(s)Ritu Salani, MD, Bhavana Pothuri, MD
Learn about the factors that influence the choice between chemotherapy re-challenge and the combination of lenvatinib and pembrolizumab for endometrial cancer treatment in the context of clinical data.
Advertisement
Episodes in this series
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer
3
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
4
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
5